Ocular Immunology, Ophthalmology, Uveitis
Uveitis; Ocular Oncology
The Johns Hopkins Hospital - Google Maps
Douglas A. Jabs, M.D., M.B.A. is an internationally-recognized expert in the evaluation and management of patients with uveitis and related immune-mediated ocular disorders, particularly on the use of immunosuppression to treat severe ocular inflammatory diseases. Founder of the Division of Ocular Immunology and Uveitis at Wilmer, he now is the Director of the Center for Clinical Trials and Evidence Synthesis at the Johns Hopkins University Bloomberg School of Public Health.
Dr. Jabs is an internationally recognized expert in clinical trials and evidence-based medicine. He has held NIH funding continuously for over 30 years. He has chaired numerous clinical trials on the treatment of uveitis, and its ocular complications.
He is the Chair of the international, NIH-funded multicenter, comparative effectiveness clinical trial, the ADVISE Trial, on the use of an anti-TNF biologic in the treatment of severe uveitides. He is the Research Group Chair of the international, NIH-funded multicenter clinical trials, the MERIT and POINT Trials, on the treatment of uveitic macular edema. He was the Chair of the international, NIH-funded, multicenter comparative effectiveness clinical trial, the MUST Trial, on the use of immunosuppression for treatment of severe uveitides.
Dr. Jabs also chaired a long-term, NIH-funded, multicenter, cohort study on the occurrence of ocular infections in immune compromised persons. He chairs the Standardization of Uveitis (SUN) Working Group, which is an international group of uveitis experts dedicated to improving clinical research in the field of Uveitis. The SUN Working Group’s current project is to define classification criteria to diagnose the leading 25 uveitides.
Patient Ratings & Comments
The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.